Tobacco carcinogen mediated up-regulation of AP-1 dependent pro-angiogenic cytokines in head and neck carcinogenesis

Molecular Carcinogenesis

Volumn 50, Issue 9, 2011, Pages 668-679

  Swenson, Wade G ^a   Wuertz, Beverly R K ^a   Ondrey, Frank G ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Activator protein 1; Cigarette smoke condensate; Head and neck cancer; IL 8; Tobacco carcinogens; VEGF

Indexed keywords

CIGARETTE SMOKE CONDENSATE; CYTOKINE; INTERLEUKIN 8; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSA; TRANSCRIPTION FACTOR FOSB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOGENESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; LARYNX CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SQUAMOUS CELL CARCINOMA; TOBACCO; TUMOR MICROENVIRONMENT; UPREGULATION;

BLOTTING, WESTERN; CARCINOGENS; CELL LINE, TUMOR; CYTOKINES; GENES, REPORTER; HEAD AND NECK NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TOBACCO; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

NICOTIANA TABACUM;

EID: 79960646135     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20775     Document Type: Article

References (63)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA-Cancer J Clin 2001; 51: 15-36.
2. Choi SY, Kahyo H. Effect of cigarette-smoking and alcohol-consumption in the eitiology of cancer of the oral cavity, pharynx and larynx. Int J Epidemiol 1991; 20: 878-885.
3. Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol-drinking, and cancer of the oral cavity and oropharynx among United-States vetrans. Cancer 1993; 72: 1369-1375.
4. Boffetta P, Mashberg A, Winkelmann R, Garfinkel L. Carcinogeneic effect of tobacco smoking and alcohol drinking on anatomic sites of the oral cavity and oropharynx. Int J Cancer 1992; 52: 530-533.
5. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287.
6. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
7. Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3530-3533.
8. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 1996; 56: 5720-5722.
9. Miyoshi Y, Tsukinoki K, Imaizumi T, et al. Telomerase activity in oral cancer. Oral Oncol 1999; 35: 283-289.
10. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2: 682-685.
11. Schepman KP, vanderWaal I. A proposal for a classification and staging system for oral leukoplakia: A preliminary study. Oral Oncol Eur J Cancer B 1995; 31B: 396-398.
12. Raju B, Mehrotra A, Oijordsbakken G, Al-Sharabi AK, Vasstrand EN, Ibrahim SO. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: Association with clinicopathological parameters. Anticancer Res 2005; 25: 4699-4706.
13. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappa B through phosphorylation and degradation of I kappa B alpha: Correlation with induction of cyclooxygenase-2. Carcinogenesis 2002; 23: 1511-1518.
14. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-kappa B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26: 119-129.
15. Rohrer J, Wuertz BRK, Ondrey F. Cigarette smoke condensate induces nuclear factor kappa-B activity and proangiogenic growth factors in aerodigestive cells. Laryngoscope 2010; 120: 1609-1613.
16. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-kappa B and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999; 59: 3495-3504.
17. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1 alpha promotes nuclear factor-kappa B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001; 7: 1812-1820.
18. Luca M, Huang SY, Gershenwald JE, Singh RK, Reich R, BarEli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-1113.
19. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996; 97: 2792-2802.
20. Kitadai Y, Takahashi Y, Haruma K, et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 1999; 81: 647-653.
21. Ferrara N, DavisSmyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
22. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth invivo. Nature 1993; 362: 841-844.
23. Ravi D, Ramadas K, Mathew BS, Nalinakumari KR, Nair MK, Pillai MR. Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol 1998; 34: 543-548.
24. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-kappa B alpha of nuclear factor-kappa B in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468-3474.
25. Mohamed KM, Le A, Duong H, Wu YD, Zhang QZ, Messadi DV. Correlation between VEGF and HIF-1 alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol 2004; 76: 143-152.
26. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene - A concert of activating factors. Cardiovasc Res 2005; 65: 564-573.
27. Schmidt D, Textor B, Pein OT, et al. Critical role for NF-kappa B-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 2007; 26: 710-719.
28. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Jagt DLV, Abcouwer SF. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: Role of nuclear factor-kappa B and activating protein-1. Cancer Res 2004; 64: 4858-4869.
29. Damert A, Ikeda E, Risau W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 1997; 327: 419-423.
30. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNF alpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008; 13: E292-E295.
31. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappa B dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2004; 29: 42-45.
32. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-1379.
33. Husgafvel-Pursiainen K. Genotoxicity of environmental tobacco smoke: A review. Mutat Res 2004; 567: 427-445.
34. Mandel I. Smoke signals - An alert for oral disease. J Am Dent Assoc 1994; 125: 872-878.
35. Haber J, Wattles J, Crowley M, Mandell R, Joshipura K, Kent RL. Evidence for cigarette-smoking as a major risk factor for periodontitis. J Periodontol 1993; 64: 16-23.
36. Ismail AI, Morrison EC, Burt BA, Caffesse RG, Kavanagh MT. Natural-history of periodontal-disease in adults - Findings from the Tecumseh periodontal-disease study, 1959-87. J Dent Res 1990; 69: 430-435.
37. Bergstrom J. Cigarette-smoking as risk factor in chronic periodontal-disease. Community Dent Oral Epidemiol 1989; 17: 245-247.
38. Taybos G. Oral changes associated with tobacco use. Am J Med Sci 2003; 326: 179-182.
39. Marx J. Cancer research - Inflammation and cancer: The link grows stronger. Science 2004; 306: 966-968.
40. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
41. Baric JM, Alman JE, Feldman RS, Chauncey HH. Inflence of cigarette, pipe, and cigar smoking, removable partial dentures, and age on oral leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1982; 54: 424-429.
42. Pindborg JJ, Kiaer J, Gupta PC, Chawla TN. Studies in oral leukoplakias - Prevalence of leukoplakia among 10, 000 persons in Lucknow India with special reference to use of tobacco and betel nut. Bull World Health Organ 1967; 37: 109-116.
43. Banoczy J, Rigo O. Prevalence study of oral precancerous lesions within a complex screening system in Hungary. Community Dent Oral Epidemiol 1991; 19: 265-267.
44. Dombi C, Voros-Balog T, Czegledy A, Hermann P, Vincze N, Banoczy J. Risk group assessment of oral precancer attached to X-ray lung-screening examinations. Community Dent Oral Epidemiol 2001; 29: 9-13.
45. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000; 60: 5879-5886.
46. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586-18594.
47. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002; 9: 62-70.
48. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K. Tumor-necrosis-factor-alpha and interferon-gamma synergistically induce interleukin-8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-KB-like binding sites of the interleukin-8 gene. J Biol Chem 1992; 267: 22506-22511.
49. Okamoto SI, Mukaida N, Yasumoto K, et al. The interleukin-8 AP-1 and KAPPA-B-like sites are genetic end targets of FK5O6-sensitive pathway accompanied by calcium mobilization. J Biol Chem 1994; 269: 8582-8589.
50. Mukaida N, Okamoto S, Ishikawa Y, Matsushima K. Molecular mechanism of interleukin-8 gene-expression. J Leukoc Biol 1994; 56: 554-558.
51. Murayama T, Ohara Y, Obuchi M, et al. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappa B-binding sites of the interleukin-8 gene. J Virol 1997; 71: 5692-5695.
52. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
53. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275: 642-650.
54. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998; 16: 2711-2721.
55. Li JJ, Cao Y, Young MR, Colburn NH. Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog 2000; 29: 159-169.
56. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E136.
57. Ness RB, Modugno F. Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur J Cancer 2006; 42: 691-703.
58. van Kempen LCL, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006; 42: 728-734.
59. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91: 459-477.
60. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomark Prev 2005; 14: 467-475.
61. Offord EA, Beard P. A member of the activator protein-1 family found in keratinocytes but not in fibroblasts required for transcription from a human papillomavirus type-18 promoter. J Virol 1990; 64: 4792-4798.
62. Chan WK, Chong T, Bernard HU, Klock G. Transcription of the transforming genes of the oncogenic human papillomavirus-16 is stimulated by tumor promoters through AP1 binding sites. Nucleic Acids Res 1990; 18: 763-769.
63. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007; 7: 317-324.